Background: Carboranes (dicarba-closo-dodecaboranes) are a class of carbon-containing polyhedral boron-cluster compounds having remarkable thermal stability and exceptional hydrophobicity. Applications of the unique structural and chemical properties offered by icosahedral carboranes in boron neutron capture therapy have received increasing attention over the past 30 years. However, these features of carboranes may allow another application as a hydrophobic pharmacophore in biologically active molecules that interact hydrophobically with receptors.
Introduction
The icosahedral carboranes (dicarba-closo-dodecaboranes), which were ¢rst synthesized in the 1960s, have unusual properties, such as (1) high boron content, (2) remarkable thermal and chemical stability, (3) a hydrophobic surface, and (4) a spherical geometry [1] . The carboranes were utilized in medicinal chemistry in the ¢eld of boron neutron capture therapy (BNCT) for incorporation of large numbers of boron atoms into tumor cells. Since the early applications of simple boroncontaining compounds for BNCT, various compounds have been synthesized by adding carborane units to amino acids, nucleic acids, porphyrins, DNA binders and carborane-containing antibodies [2, 3] . Among the properties of carboranes, the high boron content and chemical stability are useful for BNCT. However, their highly hydrophobic character prevents the incorporation of these molecules into tumor cells. Therefore, derivatization of carboranecontaining molecules has been conducted to obtain water solubility [4] . On the other hand, from the standpoint of receptor^ligand complexation, the exceptional hydrophobic character of carboranes [5, 6] may allow their use as a hydrophobic pharmacophore in biologically active molecules. This concept has been realized by the synthesis of several biologically active peptides, in which phenylalanine residues were replaced with (o-carboranyl)alanine [7^10].
However, little attention has been paid to the possible use of carborane as a hydrophobic skeletal structure, in the ¢eld of drug design. We have been engaged in the design and synthesis of new nuclear receptor ligands [11, 12] and signal transduction modulators [13, 14] , and have recognized the importance of hydrophobic interaction in receptor^ligand complexation. The di¡erence of binding constants between a ligand having a suitable hydrophobic group and a ligand without such a group sometimes reaches 100V10000 times. To evaluate the utility of icosahedral carborane as a hydrophobic component for drug design [15^17], we focused on the design and synthesis of estrogen agonists bearing a carborane cage as a hydrophobic skeletal structure [18] .
The steroid hormone estrogen in£uences the growth, di¡erentiation, and functioning of many target tissues. Estrogens play an important role in the female and male reproductive systems, and also in bone maintenance, in the central nervous system and in the cardiovascular system. The ¢rst step in the appearance of these activities is mediated by the binding of hormonal ligands to the estrogen receptors (ER) K [19] and L [20] . The hormone-bound ER undergoes a conformational change, allowing the receptor to dimerize. The dimer functions as a transcription factor that mediates biological response by binding to speci¢c promoter elements of DNA to initiate gene transcription. Compounds that either induce or inhibit cellular estrogen responses have potential value as biochemical tools and candidates for drug development. In this article, we describe the synthesis and biological evaluation of novel carborane-containing estrogenic agonists, which are more potent than 17L-estradiol.
Results

Ligand design
Since the discovery of the non-steroidal estrogen diethylstilbestrol [21] , many stilbenes, triarylethylenes and other aromatic compounds have been synthesized and shown to possess estrogenic activity. Many estrogen agonists and antagonists [22] have been developed as agents for regulating fertility, preventing and controlling hormone-responsive breast cancer, and post-menopausal hormone replacement. Estrogenic activity has been found in a large range of structural prototypes, including non-steroidal compounds isolated from plants, such as £avonoids [23] . On the other hand, the health risks of the estrogenic compounds that are either present in the environment or used as chemicals have become of interest in recent years [24] . One of the reasons for the estrogenic activity of such a wide variety of organic chemicals appears to be that ER binding is primarily the result of interaction between the receptor and a phenolic residue. Furthermore, the estrogenic activity is known to depend on the shape of the alkyl substituent in simple phenols having a bulky alkyl group at the 4-position. Therefore, high binding a¤nity for ER and the appearance of substantial estrogenic activity require an appropriate hydrophobic group adjacent to the phenolic ring, other than two hydrogen-bonding groups such as a phenolic hydroxyl group and another hydroxyl group located at a suitable position on the molecule. The C, D rings on the natural hormone, 17L-estradiol (1), play an important role in stabilizing the ligand^receptor complex by hydrophobic interactions. The size of the carborane cage seems to be appropriate for the hydrophobic skeletal structure in place of the C, D ring structure of 1. Substitution of the two carbon atoms of the carborane isomers should allow suitable ¢xation of the direction of the functional groups. On the basis of these considerations, we designed the compound BE120 (2c), which seems to contain all the essential molecular recognition components for ER. Fig. 1 shows a structural comparison of 17L-estradiol (1) and 2c. As shown in Fig. 1 , we also designed compounds 2a, 2b and 2d^f to evaluate the e¡ects of substituents and of the distance of the aliphatic hydroxyl group from the hydrophobic skeleton. In icosahedral cage structures throughout this paper, closed circles (b) represent carbon atoms and other vertices represent BH units.
Ligand synthesis
The designed molecules 2 were synthesized from 1,12-dicarba-closo-dodecaborane (p-carborane, 3) as shown in Fig. 2 . 1-(4-Methoxyphenyl)-1,12-dicarba-closo-dodecaborane (4a), which was prepared by coupling of the Ccopper (I) derivative of 3 with 4-iodoanisole in dimethoxyethane in the presence of pyridine in 60% yield [25] , was demethylated with boron tribromide to a¡ord compound 2a in 93% yield. The methoxyphenylcarborane 4a was converted to the C-methoxycarbonyl derivative 5 by reaction of the lithiate of 4a with methyl chloroformate (91%). After reduction of 5 with LiAlH 4 , demethylation gave 1-hydroxymethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closododecaborane (BE120, 2c) in 98% yield. 1-Hydroxy-12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane (2b) was prepared by oxidation of the lithiate of 4a with benzoyl peroxide [26] followed by demethylation (75%). Hydrolysis of the ester group of 5 followed by demethylation a¡orded 12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane-1-carboxylic acid (2f) in 98% yield. The acid 4f was converted to the C-t-butoxycarbonylamino derivative (6) in 41% yield by means of the modi¢ed Curtius rearrangement [27] employing diphenylphosphoryl azide (DPPA), 4-N,Ndimethylaminopyridine (DMAP) and tert-butanol. Deprotection of the Boc group of 6 followed by demethylation gave 1-amino-12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane (2g) in a quantitative yield. Compound 4a was converted to 4d by reaction of the lithiate of 4a with 2-(2-bromoethoxy)tetrahydro-2H-pyran followed by deprotection of the THP group with p-toluenesulfonic acid (45%). Demethylation of the methoxy group gave 1-hydroxyethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane (2d) in 88% yield. Similarly, introduction of a C3 unit into 4a a¡orded 1-hydroxypropyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane (2e).
Transactivational properties and ER-binding a¤nity of the designed carborane-containing molecules
The estrogenic activities of the synthesized compounds were examined by the luciferase reporter gene assay [28] , in which a rat ERK expression plasmid [29] and a reporter plasmid, which contains ¢ve copies of estrogen response elements, are transiently transfected into COS-1 cells. 17L-Estradiol at 1U10 310^1 U10 38 M induced the expression of luciferase in a dose-dependent manner. This activation by 17L-estradiol was dependent upon the expression of ER 
and was completely inhibited by estrogen antagonists (tamoxifen and ICI 164,384). The results of the estrogenic activity assay of our carborane-containing molecules (2a^g) are summarized in Fig. 3 . Compound 2a, which is a simple phenol bearing p-carboranyl at the 4-position, exhibited potent transcriptional activity in the concentration range of 1U10
310^1
U10
38 M; its potency is much higher than that of 4-alkylphenols. 1-Phenyl-1,12-dicarbacloso-dodecaborane, which lacks the hydroxyl group, showed no activity. On the other hand, the activity of compound 2b, which has a second hydrogen-bonding group on carbon of the carborane cage, was signi¢cantly increased. The potency of 2b was greater than that of 17L-estradiol. BE120 (2c), which has a hydroxymethyl group on the carborane cage, a¡orded the most potent activity, being at least 10 times more potent than 17L-estradiol. Further insertion of methylene units in the substituent on the carborane cage (2d and 2e) decreased the activity. The activity of 2g with an amino group on the carborane cage seemed to be somewhat stronger than that of 17L-estradiol, and 2f with a carboxylic acid moiety exhibited moderate activity.
ERK-binding assays were performed on the three active compounds (2a, 2c and 2g) and 17L-estradiol to con¢rm that the gene-regulatory activity correlated with the binding a¤nity for the ERK. The assays were done by measurement of inhibition of [6, H]17L-estradiol binding (K d = 0.4 nM) to human recombinant ERK (PanVera), using the nitrocellulose ¢lter binding assay method. The ERK-binding data for these compounds are consistent with the results of the luciferase reporter gene assay. Compounds 2a and 2g showed strong a¤nity for ERK; their potency was almost the same as that of 17L-estradiol. The most active compound in the luciferase reporter gene assay, 2c, also showed the highest a¤nity for ERK, and its a¤nity was higher than that of 17L-estradiol. The K i values of 2a, 2c, and 2g for ERK were 0.40, 0.10, and 0.65 nM, respectively.
Structure^activity relations of the carborane-containing estrogens
To investigate the relation between the activity and the geometry and separation distance of the two hydroxyl groups on the phenylcarborane skeleton, we designed and synthesized compounds bearing a para-substituent on the carborane cage and a 3-hydroxyl group on the benzene nucleus (7a^e), compounds bearing a substituted meta-carborane cage and a 4-hydroxyl group on the benzene nucleus (8a^e) and compounds bearing a substituted meta-carborane cage and a 3-hydroxyl group on the benzene nucleus (9a^e), in the same manner as described for 2a^2e (Fig. 4) . The transcriptional activity of compounds 7, 8, and 9 is summarized in Fig. 5 . The activity of the compounds bearing a para-substituent on the carborane cage and a 3-hydroxyl group on the benzene nucleus (3) was somewhat weaker than that of 2, and showed the same tendency upon insertion of methylene groups as in the series of 2. However, the potency of 1-hydroxymethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closo-dodecaborane 7c was still greater than that of 17L-estradiol. The activity of the compounds bearing a meta-substituent on the carborane cage and a 4-hydroxyl group on the benzene nucleus (8) was weaker than that of 7. Further, the activity of the compounds bearing a meta-substituent on the carborane cage and a 3-hydroxyl group on the benzene nucleus (9) was greatly decreased, being similar to that of the typical estrogenic alkylphenol 4-tert-octylphenol.
2.5. E¡ects of the carborane-containing estrogens on uterine atrophy and bone loss in ovariectomized mice
Estrogen de¢ciency results in uterine atrophy and a marked bone loss, and these phenomena can be restored by estrogen administration [30] . Using ovariectomized (OVX) mice, we compared the e¡ects of 17L-estradiol and 2c on the uterus. The uterine weight decreased markedly in OVX mice, indicating that the mice were estrogende¢cient as shown in Fig. 6 . As reported previously, 17L-estradiol (100 ng/day) restored the decreased uterine weight in OVX mice to a level higher than that of the sham-operated mice. Compound 2c (100 ng/day) also restored the uterine weight of OVX mice, and its potency was similar to that of 1 (Fig. 6A ). This indicates that 2c exhibits a potent estrogenic action in the uterus in vivo.
To determine the e¡ects of 2c on bone mass, OVX mice were treated for 4 weeks with 100 ng/day of 2c and the femurs were subjected to radiographic analysis. X-ray analysis showed a marked loss of mineralized cancellous bone, especially in the distal metaphysis of the femur, in OVX mice [31] . Treatment with 17L-estradiol or 2c at 100 ng/day markedly and similarly prevented the bone loss in the distal metaphysis in OVX mice (Fig. 6B ). The e¡ects of 2c on bone mass were determined by measuring bone mineral density (BMD) at a distal region of the femur. BMD was signi¢cantly reduced by OVX but recovered completely on the administration of 100 ng/day of 2c to the sham level. 17L-Estradiol at the same dosage also restored the BMD, as reported previously. These results suggest that 2c binds to estrogen receptor(s) present in uterus and bone, and exhibits estrogen-like e¡ects in both tissues.
Discussion
Recent studies on the three-dimensional structure of the complex formed by 17L-estradiol and the human ERK ligand-binding domain (hERKLBD) have revealed the structural requirements for the appearance of estrogenic activity [32, 33] . 17L-Estradiol is oriented in the hERK ligand-binding pocket by two types of contacts: hydrogen bonding at both ends and hydrophobic van der Waals contacts along the body of the skeleton. The phenolic hydroxyl group is hydrogen-bonded to the glutamate (Glu-353) of hERKLBD and the 17-L-hydroxyl group is hydrogen-bonded to the N-nitrogen of His-524. Docking simulations to this structure (1ERE : Fig. 7A ) would be useful to clarify the relation between the three-dimensional structures and high activity of carborane-containing estrogens. These simulations were performed using an automatic docking program (ADAM; not publicly distributed, only available for collaborators on contract basis) [34] . The most potent carborane-containing estrogen 2c was well-¢tted to the cavity of the X-ray structure of hERKLBD. Compound 2c is oriented in the cavity as shown in Fig. 7B by two types of contacts: hydrogen bonding at both ends and hydrophobic van der Waals contacts along the body of the skeleton, as found for 17L-estradiol (1) in the X-ray structure. Compound 2b, Fig. 6 . E¡ects of 1 and 2c on the uterine weight and bone mineral density (BMD) of femurs in OVX mice. Mice were sham-operated or OVX, and some of the OVX mice were treated with 1^100 ng/day of 2c or 100 ng/day of 1 immediately after the operation. Numbers in parentheses are doses of the test compounds per day (ng). At 4 weeks after the operation, uterine weight (A) and BMD of the distal femur (B) were measured. The upper panel in B shows soft X-ray radiograms of the femurs collected from animals of each group. Note that marked bone loss occurred in the femoral cancellous bone in OVX mice, and that the bone loss was completely prevented by the treatment with 100 ng/day of 2c or 1. Data are expressed as the means þ S.E.M. of 6^8 mice.
with a hydroxyl group directly substituted on the carborane cage, and the 3-hydroxy isomer 7c were also well-¢tted to the cavity of hERKLBD (Fig. 7C,D) . Table 1 shows the heteroatom^heteroatom distances of compounds 2a, 2b, 2c, 3b, 7c, 8c, and 9c in the most stable docking models, and that in the crystal structure of 1. The relation between heteroatom^heteroatom distances and biological activity suggested that three distances within 3.2 A î seem to be e¡ective for hydrogen bondings. However, the interactions of the ligands to the receptor cannot be explained only in terms of hydrogen bonding, but also hydrophobic interaction. The lack of one hydrogen bond might be compensated for by an e¡ective hydrophobic interaction. The hydrophobic interaction along the spherical carborane cage seems to produce a stronger interaction than that in the case of 17L-estradiol. This may be the reason for the high activity of compound 2a, which lacks a hydroxyl group for hydrogen bonding to the N-nitrogen of His-524 (Fig. 7E) . Compound 2a has signi¢cant potency compared to wellknown estrogenic 4-alkylphenols [35] , 4-cycloalkylphenols [36] , and 4-(1-adamantyl)phenol [36] (Fig. 7F) . Therefore, use of this new hydrophobic and spherical component, the carborane cage, for molecular drug design should make it possible to develop a wide variety of biologically active molecules, especially nuclear receptor ligands.
In summary, we have developed novel carborane-containing molecules with potent estrogenic activity. The unique character of biologically active molecules containing a carborane skeleton may give rise to unusual membrane transport characteristics and metabolism, compared with conventional active molecules. The superagonistic properties of the carborane-containing compounds raise the possibility that structure^function studies could lead to the development of more selective estrogen agonists and antagonists, which could be useful as therapeutic agents for a wide variety of conditions.
Signi¢cance
Carboranes (dicarba-closo-dodecaboranes) are a class of carbon-containing polyhedral boron-cluster compounds having remarkable thermal stability and exceptional hydrophobicity. These features of carboranes may allow their use as a hydrophobic pharmacophore in biologically active molecules that interact hydrophobically with receptors. We therefore designed candidate estrogen-receptorbinding compounds having carborane as a hydrophobic moiety (2) and synthesized them. Their estrogenic activity was examined by the luciferase reporter gene assay using COS-1 cells transfected with rat ERK expression plasmid and an appropriate reporter plasmid. The most potent compound bearing a carborane cage (BE120, 2c) exhibited potent activity in the concentration range of 1U10
3101
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38 M; its potency is at least 10-fold greater than that of 17L-estradiol. In vitro ERK-binding data for these compounds were consistent with the results of the luciferase reporter gene assay. These results con¢rm that the gene-regulatory activity of the carborane-containing compounds is correlated with their binding a¤nity for the ER. The most active compound in the luciferase reporter gene assay, BE120, also showed the highest a¤nity for ERK. The compound also showed potent in vivo e¡ects on the recovery of uterine weight and bone loss in OVX mice. Development of the potent carborane-containing estrogenic agonists described here should yield novel candidate therapeutic agents, especially selective ER modulators. Furthermore, the suitability of the spherical carborane cage for binding to the cavity of ERKLBD should provide a basis for a similar approach to developing novel ligands for other steroid receptors.
Materials and methods
Synthesis
(4a) To a solution of 1,12-dicarba-closo-dodecaborane (3, 3.5 g, 24.3 mmol) in 1,2-dimethoxyethane (95 ml) was added dropwise a 1.54 M solution of n-BuLi in hexane (16.6 ml, 25.6 mmol) at 0³C under Ar. The mixture was stirred at room temperature for 30 min, and CuCl (3.13 g, 31.6 mmol) was added in one portion. Stirring was continued at room temperature for 1 h, then pyridine (14.7 ml, 183 mmol) was added, and 4-iodoanisole (5.97 g, 25.5 mmol) was further added in one portion, and the mixture was heated at 100³C for 48 h. After cooling, the reaction mixture was diluted with Et 2 O and stirred at room temperature for 3 h. Insoluble materials were ¢ltered o¡ through Celite. The ¢ltrate was washed with 2 N HCl, aq. Na 2 S 2 O 3 , H 2 O, and brine, dried over Na 2 SO 4 , then concentrated. Puri¢cation by silica gel column chromatography (eluent: hexane to hexane/AcOEt, 10:1) gave 4a (60%) and 1,12-bis(4-methoxyphenyl)-1,12-dicarba-closo-do- 
To a solution of 4a (500 mg, 2.00 mmol) in benzene/Et 2 O (2:1, 15 ml) was added dropwise a 1.54 M solution of n-BuLi in hexane (1.56 ml, 2.40 mmol) at 0³C under Ar. The mixture was stirred at room temperature for 30 min and cooled to 0³C, then methyl chloroformate (227 mg, 2.40 mmol) was added dropwise and stirring was continued at room temperature for 3 h. The reaction was quenched with water and the whole was extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , and concentrated. Puri¢cation by silica gel £ash column chromatography (eluent: hexane/AcOEt, 50:1) gave 5 (91%). 5.1.6. 1-Hydroxyethyl-12-(4-hydroxyphenyl)-1,12-dicarba-closododecaborane (2d) To a solution of 4a (200 mg, 0.80 mmol) in benzene/Et 2 O (2:1, 7.5 ml) was added dropwise a 1.54 M solution of n-BuLi in hexane (0.623 ml, 0.953 mmol) at 0³C under Ar. The mixture was stirred at room temperature for 30 min and cooled to 0³C, then O-tetrahydropyranyl-2-bromoethanol (231 mg, 1.20 mmol) was added dropwise and stirring was continued at room temperature for 15 h. The reaction was quenched with water and the whole was extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , and concentrated. Puri¢cation by silica gel £ash column chromatography (eluent : hexane/CH 2 Cl 2 , 2:1) gave the C-alkylated product (45%). 1 
1-Hydroxycarbonyl-12-(4-hydroxyphenyl)-1,12-dicarbacloso-dodecaborane (2f)
To a solution of 5 (260 mg, 0.843 mmol) in THF (3 ml) was added 1 N KOH (4.22 ml), and the mixture was stirred at room temperature for 17 h. The reaction was quenched with 2 N HCl and the whole was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4 , then concentrated to give 1-hydroxycarbonyl-12-(4-methoxyphenyl)-1,12-dicarba-closo-dodecaborane (4f) (quant. 
1-(3-Methoxyphenyl)-1,12-dicarba-closo-dodecaborane (10a)
Compound 10a was prepared from 1,12-dicarba-closo-dodecaborane (3) and 3-iodoanisole by the same method as used for preparation of 4a (Fig. 8) . Puri¢cation by silica gel column chromatography (eluent : hexane/AcOEt, 100:1 to 10:1) gave 10a (61%) and 1,12-bis(3-methoxyphenyl)-1,12-dicarba-closo-dodecaborane (10% 5.1.18. 1-(4-Methoxyphenyl)-1,7-dicarba-closo-dodecaborane (13a) To a solution of 1,7-dicarba-closo-dodecaborane (12, 3.5 g, 24.3 mmol) in 1,2-dimethoxyethane (95 ml) was added dropwise a 1.54 M solution of n-BuLi in hexane (16.6 ml, 25.6 mmol) at 0³C under Ar (Fig. 9) . The mixture was stirred at room temperature for 30 min, then CuCl (3.13 g, 31.6 mmol) was added in one portion and stirring was continued at room temperature for 1 h. Pyridine (14.7 ml, 183 mmol) was added, then 4-iodoanisole (5.97 g, 25.5 mmol) was further added in one portion, and the mixture was heated at 100³C for 48 h. After cooling, the reaction mixture was diluted with Et 2 O and stirred at room temperature for 15 h. Insoluble materials were ¢ltered o¡ through Celite. The ¢ltrate was washed with 2 N HCl, aq. Na 2 S 2 O 3 , H 2 O and brine, dried over Na 2 SO 4 , then concentrated. Puri¢cation by silica gel column chromatography (eluent : hexane to hexane/AcOEt, 30:1) gave 13a (42%) and 1,7-bis(4-methoxyphenyl)-1,7-dicarba-closo-dodecaborane (17%). 
1-(4-Hydroxyphenyl)-1,7-dicarba-closo-dodecaborane (8a)
Compound 8a was synthesized from 13a by the same method as used for preparation of 2a. Puri¢cation by silica gel £ash column chromatography (eluent : hexane/AcOEt, 10:1) gave 8a. 5.1.25. 1-(3-Methoxyphenyl)-1,7-dicarba-closo-dodecaborane (15a) Compound 15a was prepared from 1,7-dicarba-closo-dodecaborane (12) and 3-iodoanisole by the same method as used for preparation of 13a (Fig. 10) . Puri¢cation by silica gel column chromatography (eluent: hexane/AcOEt, 100:1 to 50:1) gave 15a (39%) and 1,7-bis(3-methoxyphenyl)-1,7-dicarba-closo-dodecaborane (14% 
Transfection and luciferase assays
The ER expression plasmid, pCI-rERK, was constructed by inserting the rat uterus ER cDNA (pUCER6, which was obtained from the Health Science Research Resources Bank, Osaka, Japan) into the expression vector pCI-neo (Promega). The reporter plasmid, EREx5-pGL-TK, was constructed by introducing ¢ve copies of the estrogen response element (ERE), caAGGTCAcccTGACCTcc, and the herpes simplex virus thymidine kinase promoter into the NheI^HindIII sites of the pGL3-Basic luciferase reporter vector (Promega). The COS-1 cells were obtained from the Japanese Cancer Research Resources Bank (JCRB) and were maintained in Dulbecco's modi¢ed essential medium (DMEM), supplemented with 5% fetal bovine serum (FBS). For the reporter gene assay, COS-1 cells were seeded in 24-well tissue culture plates at 6U10 4 cells per well with 5% charcoal-stripped FBS/ DMEM without phenol red. The cells were cultured at 37³C in 5% CO 2 overnight and allowed to attach to the plates. Then, the medium was removed and the transfection was performed with the cationic lipid transfection reagent Tfx-20 (Promega). Liposomes were formed by incubating 100 ng of pCI-rERK, 50 ng of EREx5-pGL-TK, and 100 ng of the reference plasmid pCMVL (Clontech) with 0.75 Wl of Tfx-20 in phenol red-free DMEM (¢nal 200 Wl) for 10^15 min at room temperature. These DNA/ Tfx-20 mixtures were added to the cells and the culture plates were returned to the CO 2 incubator. After 2 h, 800 Wl of DMEM supplemented with charcoal-stripped FBS (¢nal 0.5%) and 5 Wl of ethanol solution of ligands were added. After an additional 18 h of incubation, the cells were harvested, and the luciferase assay was performed with the Luciferase Assay System (Promega). The luciferase activities were normalized to L-galactosidase activities. Each condition was assayed in triplicate.
ERK ligand-binding assays
The ligand-binding activity of ERK was determined by the nitrocellulose ¢lter binding assay method. ERK (0.5 Wg/tube, PanVera Co. Ltd.) was diluted with a binding assay bu¡er (20 mM Tris^HCl pH 8.0, 0.3 M NaCl, 1 mM EDTA pH 8.0, 10 mM 2-mercaptoethanol, 0.2 mM phenylmethylsulfonyl £uoride) and incubated with 4 nM [6,7- 3 H]17L-estradiol in the presence or absence of an unlabeled competitor at 4³C for 16 h. The incubation mixture was absorbed by suction onto a nitrocellulose membrane that had been soaked in binding assay bu¡er. The membrane was washed twice with bu¡er (20 mM Tris^HCl pH 8.0, 0.3 M NaCl) and then with 25% ethanol in distilled water. Radioactivity that remained on the membrane was measured in Atomlight (NEN) using a liquid scintillation counter.
Animal studies
Eight-week-old female mice of the ddy strain were obtained from Japan SLC Inc. (Shizuoka, Japan). Mice were either sham-operated or OVX, and some of the OVX mice were subcutaneously administered either 1^100 ng/day of 2c or 100 ng/day of 17L-estradiol (1) dissolved in polyethyleneglycol 300 using a miniosmotic pump (Alza Co.), immediately after the surgery. At 4 weeks after the surgery, the mice were killed and the weight of the uterus was measured, and the right and left femurs were removed to measure BMD.
Radiographic analysis of the femur
Radiographic photographs of the femurs were taken with soft X-rays (model CMB-2, SOFTEX). The BMD of the femurs was measured by dual X-ray absorptiometry (model DCS-600R, Aloka). The bone mineral content (BMC) of the mouse femur was correlated closely with the ash weight. BMD was calculated by dividing BMC of the measured area by the area. The scanned area was divided into three parts: proximal femur, midshaft, and distal femur.
Docking simulation
The most stable docking models for all compounds were estimated using the automatic docking program ADAM version 4.11 [34] . Energy minimization of the docking models was done by the SANDER module of the AMBER 5 program package. Energy decomposition analyses of the ¢nal docking models were done by the ANAL module of AMBER 5 [37] . The structure of the human ERKLBD was obtained from the crystal structure of the ERKLBD complex (PDB code 1ERE A-chain) by removing the 17L-estradiol molecule. All hydrogen atoms that are missing in the crystal structure but should exist in the protein structure were computationally located at appropriate positions and optimized further by the AMBER program.
